Please login to the form below

Not currently logged in
Email:
Password:

Roche to cease HIV research

Roche, the Swiss pharmaceutical company, is to cease research into HIV as none of its pending medicines represent a significant improvement over existing drugs
Roche, the Swiss pharmaceutical company, is to cease research into HIV as none of its pending medicines represent a significant improvement over existing drugs.

A report, published by Reuters, references a memo sent to Aids specialists and activists saying that, due to poor results in clinical trials, the company had cancelled its current product development programmes.

Confirming the contents of the memo, a spokeswoman based in Roche's US office said the company has "decided to refocus our resources within virology on diseases in which we can deliver substantial improvements over existing medications."

"Research scientists currently working in HIV will be reassigned to other activities," said the spokeswoman.

According to figures published by independent market research firm, Datamonitor, a small increase in HIV cases and the launch of new drugs means that the AIDS medicine market is set to be worth $10.6bn by 2015.

According to the report, Roche said it would reassess its involvement in this area should a scientific breakthrough in HIV occur elsewhere. The company has vowed to continue supporting its molecular diagnostic tests and medications already on the market.

14th July 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics